Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G, Bartels L, Kedde M, Verdegaal EME, Gillissen MA, Levie SE, Cercel MG, van Hal-van Veen SE, Fatmawati C, van de Berg D, Yasuda E, Claassen YB, Bakker AQ, van der Burg SH, Schotte R, Villaudy J, Spits H, Hazenberg MD, van Helden PM, Wagner K. de Jong G, et al. Among authors: kedde m. Cancer Immunol Immunother. 2021 Jun;70(6):1569-1581. doi: 10.1007/s00262-020-02780-9. Epub 2020 Nov 23. Cancer Immunol Immunother. 2021. PMID: 33225419 Free PMC article.
AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses.
Gillissen MA, Kedde M, Jong G, Moiset G, Yasuda E, Levie SE, Bakker AQ, Claassen YB, Wagner K, Böhne M, Hensbergen PJ, Speijer D, van Helden PM, Beaumont T, Spits H, Hazenberg MD. Gillissen MA, et al. Among authors: kedde m. Blood. 2018 Jan 4;131(1):131-143. doi: 10.1182/blood-2017-02-768762. Epub 2017 Oct 23. Blood. 2018. PMID: 29061569 Free article.
Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice.
Gillissen MA, de Jong G, Kedde M, Yasuda E, Levie SE, Moiset G, Hensbergen PJ, Bakker AQ, Wagner K, Villaudy J, van Helden PM, Spits H, Hazenberg MD. Gillissen MA, et al. Among authors: kedde m. Blood Adv. 2017 Aug 18;1(19):1551-1564. doi: 10.1182/bloodadvances.2017008342. eCollection 2017 Aug 22. Blood Adv. 2017. PMID: 29296797 Free PMC article.
RNA-binding protein Dnd1 inhibits microRNA access to target mRNA.
Kedde M, Strasser MJ, Boldajipour B, Oude Vrielink JA, Slanchev K, le Sage C, Nagel R, Voorhoeve PM, van Duijse J, Ørom UA, Lund AH, Perrakis A, Raz E, Agami R. Kedde M, et al. Cell. 2007 Dec 28;131(7):1273-86. doi: 10.1016/j.cell.2007.11.034. Cell. 2007. PMID: 18155131 Free article.
Telomerase-independent regulation of ATR by human telomerase RNA.
Kedde M, le Sage C, Duursma A, Zlotorynski E, van Leeuwen B, Nijkamp W, Beijersbergen R, Agami R. Kedde M, et al. J Biol Chem. 2006 Dec 29;281(52):40503-14. doi: 10.1074/jbc.M607676200. Epub 2006 Nov 10. J Biol Chem. 2006. PMID: 17098743 Free article.
miR-148 targets human DNMT3b protein coding region.
Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. Duursma AM, et al. Among authors: kedde m. RNA. 2008 May;14(5):872-7. doi: 10.1261/rna.972008. Epub 2008 Mar 26. RNA. 2008. PMID: 18367714 Free PMC article.
A phase I study of monohydroxyethylrutoside in healthy volunteers.
Willems AM, Bruynzeel AM, Kedde MA, van Groeningen CJ, Bast A, van der Vijgh WJ. Willems AM, et al. Among authors: kedde ma. Cancer Chemother Pharmacol. 2006 May;57(5):678-84. doi: 10.1007/s00280-005-0083-7. Epub 2005 Sep 1. Cancer Chemother Pharmacol. 2006. PMID: 16136309 Clinical Trial.
18 results